U.S. drug regulators may allow companies to restart clinical trials centered on osteoarthritis painkillers that carry a risk of joint damage, according to a Reuters report.
Pfizer, Regeneron Pharmaceuticals and Johnson & Johnson are now proposing to resume the trials, which the FDA suspended in 2010 after nearly 500 study participants needed to have joints replaced. FDA advisers will vote today on potential options for continuing the trials, including limiting the drug dosage and administering the drug only to people with fewer treatment options, such as terminal patients with severe bone pain.
KURE Pain Management in Maryland Welcomes New Pain Specialist
Alabama 2012 Pain Research Symposium to Welcome Diverse Research Panel
Pfizer, Regeneron Pharmaceuticals and Johnson & Johnson are now proposing to resume the trials, which the FDA suspended in 2010 after nearly 500 study participants needed to have joints replaced. FDA advisers will vote today on potential options for continuing the trials, including limiting the drug dosage and administering the drug only to people with fewer treatment options, such as terminal patients with severe bone pain.
Related Articles on Pain Management:
Kentucky House Approves Pain Clinic Regulation BillKURE Pain Management in Maryland Welcomes New Pain Specialist
Alabama 2012 Pain Research Symposium to Welcome Diverse Research Panel